Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2014
Price :
$35
*
At a glance
- Drugs Timbetasin (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions
- Sponsors RegeneRx Biopharmaceuticals
- 10 Jul 2014 New trial record